Ielmag3

Mertiatide, the active ingredient in Ielmag3, is a buffered phosphate solution presented as an intravenous formulation for use in clinical settings. Originating from the European Union market, it is formulated to maintain physiological pH and provide phosphate ions during infusion.

GNH USA supplies Ielmag3 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ielmag3 (Mertiatide) is a buffered phosphate solution intended for intravenous administration, but specific therapeutic indications have not been publicly disclosed.

- Electrolyte balance research: Supports studies evaluating phosphate homeostasis. - Renal replacement therapy investigations: Used in experimental dialysis protocols. - Pharmacokinetic studies: Serves as a reference solution in IV drug delivery research.

Adverse reactions associated with Ielmag3 have not been extensively documented, and reported events are limited to those typical of intravenous phosphate solutions.

Common Side Effects: - Injection site discomfort: Mild pain or irritation at the infusion site. - Transient hyperphosphatemia: Temporary elevation of serum phosphate levels. - Mild nausea: Occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe hyperphosphatemia: Marked increase in phosphate that may require medical intervention. - Allergic reaction: Rash, itching, or anaphylaxis in susceptible individuals. - Hypocalcemia: Low calcium levels secondary to phosphate shifts. - Renal impairment: Worsening kidney function in patients with pre‑existing disease.

When using Ielmag3, clinicians should observe several safety measures to minimize risks.

- Assess renal function: Evaluate baseline kidney performance before administration. - Monitor serum phosphate: Check levels during and after infusion. - Check calcium status: Avoid concurrent calcium overload. - Avoid in patients with severe hyperphosphatemia: Contraindicated in this population. - Use with caution in patients receiving calcium‑containing IV solutions: Adjust dosing as needed. - Store at ambient temperature: Keep in original container, protect from moisture and direct sunlight.

Ielmag3 may interact with other agents that affect phosphate or calcium balance.

Major Interactions (Avoid): - Calcium‑containing IV solutions: May precipitate calcium phosphate and reduce efficacy. - Aluminum‑containing antacids: Can increase phosphate absorption leading to toxicity.

Moderate Interactions (Monitor Closely): - Vitamin D supplements: May enhance phosphate absorption and raise serum levels. - Renal replacement therapy: Adjust dosing based on altered clearance. - Loop diuretics: May affect overall electrolyte balance and require monitoring.